Market research
VRP.LSE Verona Pharma plc
LSE GBP Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 228M
- P/E ratio
- Not available
- Analyst target
- 247.67
- Dividend yield
- 0.0%
- Beta
- -0.49
Profile
Instrument facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- GB00BYW2KH80
- Market cap
- 228M
- P/E ratio
- Not available
- Analyst target
- 247.67
- Dividend yield
- 0.0%
- Beta
- -0.49
About
About Verona Pharma plc
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on develops and commercializes therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine (RPL554), is an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The formulations of ensifentrine are under development for the treatment chronic obstructive pulmonary disease (COPD): nebulized ensifentrine is in Phase 2b clinical development for the maintenance treatment of COPD; and a dry powder inhaler and a pressurized metered-dose inhaler. The company also focuses on developing ensifentrine for the treatment of cystic fibrosis and asthma. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.
Research context
Verona Pharma plc appears in PyInvesting’s London Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the VRP.LSE discussion.
5 years, 6 months ago
Verona Pharma plc is currently in a long term downtrend where the price is trading 6.8% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Verona Pharma plc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 59.3% to $-20M since the same quarter in the previous year.
Finally, its free cash flow fell by 38.9% to $-10M since the same quarter in the previous year.
Based on the above factors, Verona Pharma plc gets an overall score of 1/5.